Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas

Kevin J. Hamblett, Julia Cochran, Katie Snead, Steven Jin, Roma Yumul, Jessica Simmons, Ivan Stone, Ryan Lyski, Jason P. Schrum, Andrea R. Lim, Astrid Clarke

Blood (2023) 142 (Supplement 1): 1440.

https://doi.org/10.1182/blood-2023-182400

Published: 2023

Journal Articles

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Ekaterina Kim, PhD, Elisa Ten Hacken, PhD, Astrid Clarke, PhD, Michael J. Keating, MD, William G Wierda, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Philip A Thompson, MBBS, Zeev Estrov, MD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3844.

https://doi.org/10.1182/blood.V130.Suppl_1.3844.3844

Published: 2017

Journal Articles

Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines

Jamie Bates, Saritha Kusam, Stacey Tannheimer, Astrid Clarke, Thomas Kenney, David Breckenridge, Daniel Tumas

Blood (2016) 128 (22): 5104.

https://doi.org/10.1182/blood.V128.22.5104.5104

Published: 2016

Journal Articles

The Combination of Entospletinib and Vincristine Demonstrates Synergistic Activity in a Broad Panel of Hematological Cancer Cell Lines and Anti-Tumor Efficacy in a DLBCL Xenograft Model

Mark Joseph Axelrod, PhD, Peter Fowles, Jeff Silverman, PhD, Astrid Clarke, PhD, Jennifer Tang, Emma Rousseau, M.S., Heather Kay Webb, PhD, Julie Di Paolo, PhD

Blood (2015) 126 (23): 5123.

https://doi.org/10.1182/blood.V126.23.5123.5123

Published: 2015

Journal Articles

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

Russell T Burke, Astrid Clarke, Sarah A Meadows, Marc M Loriaux, MD, PhD, Jennifer B Dunlap, MD, Guang Fan, MD, PhD, Patricia Maciejewski, Julie Di Paolo, Brian J. Lannutti, PhD, Brian J. Druker, Stephen E Spurgeon, MD

Blood (2012) 120 (21): 3876.

https://doi.org/10.1182/blood.V120.21.3876.3876

Published: 2012

NARROW

SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines

The Combination of Entospletinib and Vincristine Demonstrates Synergistic Activity in a Broad Panel of Hematological Cancer Cell Lines and Anti-Tumor Efficacy in a DLBCL Xenograft Model

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

Email alerts

ASH Publications

American Society of Hematology

SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines

The Combination of Entospletinib and Vincristine Demonstrates Synergistic Activity in a Broad Panel of Hematological Cancer Cell Lines and Anti-Tumor Efficacy in a DLBCL Xenograft Model

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only